Sermorelin 2mg

Native GHRH(1-29) is rapidly inactivated by enzymatic (DPP-IV) cleavage in plasma, so sermorelin is shorter-acting than modified analogues such as CJC-1295 Without DAC 10mg or Tesamorelin 5mg. It is therefore used as the unmodified reference in GHRH analogue comparisons.

Evidence status: sermorelin acetate was previously marketed in the United States as Geref (FDA approvals in 1990 and 1997). The manufacturer discontinued it in 2008, and the FDA later determined that it was not withdrawn for reasons of safety or effectiveness (Federal Register, 4 March 2013). Those data concern a licensed formulation; they do not describe or verify the research material supplied here. No certificate is published yet for the 2mg format; the Sermorelin 5mg report does not cover 2mg vials.

For researchers designing GHRH analogue comparison studies, sermorelin 2mg occupies the unmodified reference position. CJC-1295 Without DAC 10mg provides the DPP-IV-resistant modified 29-amino acid comparison, while Tesamorelin 5mg provides the full 44-amino acid comparison. Running all three as independent treatment arms allows researchers to dissect the contribution of sequence length, DPP-IV resistance, and N-terminal modification to receptor engagement and GH secretion dynamics. Ipamorelin 5mg acts at GHS-R1a rather than the GHRH receptor; in whole-animal designs both classes raise GH, so combined arms need appropriate controls.

The 2mg format is appropriate for pilot investigations, pharmacokinetic time-course assays where multiple time-point samples require limited compound volume per arm, and first-time sermorelin research. For established programmes requiring extended multi-arm designs, Sermorelin 5mg provides the advanced format.

Mechanism background and published references are available in the sermorelin 2mg research guide on the Ascend Peptides UK blog.